Group items tagged

The reproducibility and comparability of research on dietary supplements is enhanced by rigorous analytical characterization of key experimental materials and the publication of validated analytical methods that accurately and precisely characterized and quantify constituents in dietary supplement ingredients and products. This FOA builds on existing NIH awards to support the performance and publication of formal single-laboratory validation studies of quantitative analytical methods. The methods proposed for validation must be used to identify and quantify dietary supplement-relevant chemical constituents (i.e., active or marker chemical compounds, adulterants, contaminants) or their metabolites in experimental reagents, raw materials, and/or clinical specimens (e.g., urine or plasma samples). Methods must have been developed or utilized in fulfillment of the active parent grant's specific aims. Candidate constituents for quantitative method validation studies include (but are not limited to): phytochemicals, nutrients, and potentially deleterious substances such as pesticides and mycotoxins. Multi-laboratory validation studies will not be supported through this FOA.

The Understanding the Rules of Life: Microbiome Theory and Mechanisms (URoL:MTM) program is an integrative collaborationacross Directorates and Offices within the National Science Foundation. The objective of URoL:MTM is to understand and establish the theory and mechanisms that govern the structure and function of microbiomes, a collection of microbes in a specific habitat/environment. This may include but is not limited to host-associated microbiomes, such as those with humans and other organisms, where i) the microbiome impacts host physiology, behavior, development, and fitness; ii) the host influences the metabolic activity, dynamics and evolution of the microbiome, and iii) the environment (biological, chemical, physical, and social) influences and is influenced by both the host and the microbiome. Recent progress has transformed our ability to identify and catalogue the microbes present in a given environment and measure multiple aspects ofbiological, chemical, physical, and social environments that affect the interactions among the members of the microbiome, the host, and/or habitat. Much descriptive and correlative work has been performed on many microbiome systems, particularly those in the human, soil, aquatic, and built environments. This research has resulted in new hypotheses about the microbiome's contributions to potential system function or dysfunction. The current challenge is to integrate the wide range of accumulated data and information and build on them to develop new causal/mechanistic models or theories of interactions and interdependencies across scales and systems.

As Synthetic Biology is the attempt to engineer biology, projects should incorporate engineering principles like modularity, abstraction, standardization and orthogonality and use modelling approaches to  optimize or improve a biological or bio-based unit. Unlike descriptive biological disciplines, projects are expected to use deliberate (re)design and construction of parts, devices or systems. Projects can  derive from basic research or more applied research areas in chemical biology, biophysics, biotechnology or biomedicine. Potential advances for society should be outlined in the proposal. 

The Klarman Family Foundation is interested in providing strategic investment in translational research that will accelerate progress in developing effective treatments for anorexia nervosa, bulimia nervosa and binge eating disorder. The Program's short-term goal is to support the most outstanding science and expand the pool of scientists whose research explores the basic biology of feeding, anorexia nervosa, bulimia nervosa, and/or binge eating disorder. The long-term goal is to improve the lives of patients suffering from these conditions. Examples of funding areas include but are not limited to molecular genetic analysis of relevant neural circuit assembly and function; genetic and epigenetic research; animal models created by genetically altering neural circuits; and testing of new chemical entities that might be used in animal models as exploratory treatments.  Please note that imaging studies involving humans are not eligible. Investigators conducting research in the neuro-circuitry of fear conditioning or reward behavior may also apply but must justify the relevance of their research projects to the basic biology of eating disorders. Clinical psychotherapeutic studies, medication trials and research in the medical complications of these disorders are outside the scope of this Program.

To that end, the foundation awards grants to organizations and programs that advance the prevention, diagnosis, and treatment of alcoholism, chemical dependency, and addictive behavior, including support for related research and education.

As stated in the Strategy for American Leadership in Advanced Manufacturing, worldwide competition in manufacturing has been dominated in recent decades by the maturation, commoditization, and widespread application of computation in production equipment and logistics, effectively leveling the global technological playing field and putting a premium on low wages and incremental technical improvements.[1] The next generation of technological competition in manufacturing will be dictated by inventions of new materials, chemicals, devices, systems, processes, machines, design and work methods, social structures and business practices. Fundamental research will be required in robotics, artificial intelligence, biotechnology, materials science, sustainability, education and public policy, and workforce development to take the lead in this global competition. The research supported under this solicitation will enhance U.S. leadership in manufacturing far into the future by providing new capabilities for established companies and entrepreneurs, improving our health and quality of life, and reducing the impact of manufacturing industries on the environment.

The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the discovery and development of medications to treat Cannabis Use Disorders (CUDs) using the UG3/UH3 mechanism. The objective is to advance medications toward the ultimate goal of obtaining FDA approval. Advances in understanding the cannabinoid systems and the effects of marijuana on the brain, coupled with the availability of both novel and marketed medications that may be efficacious to treat these disorders, offer unprecedented opportunities to develop safe and effective pharmacotherapies for CUDs. The compounds to be evaluated can be small molecules or biologics. They can be tested in pre-clinical models and/or for the clinical manifestations of CUDs or their consequences such as withdrawal, craving, or cannabis use relapse. Applications may focus on the development of new chemical entities, new formulations of marketed medications available for other indications, or combinations of medications that hold promise for the treatment of CUDs. The UG3/UH3 Phase Innovation Awards Cooperative Agreement involves 2 phases. The UG3 is to support a project with specific milestones to be accomplished by the end of the 2-year period. The UH3 is to provide funding for 3 years to a project that successfully completed the milestones set in the UG3. UG3 projects that have met their milestones will be administratively considered by NIDA and prioritized for transition to the UH3 phase. Investigators responding to this FOA must address both UG3 and UH3 phases.

The Blueprint Neurotherapeutics Network (BPN) invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis including under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize promising hit compounds through medicinal chemistry, or at the Development stage, to advance a development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Projects that enter at the Discovery stage and meet their milestones may continue on through Development. BPN awardee Institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN contractors (and thereby control the patent prosecution and licensing negotiations) for drug candidates developed in this program.

The Blueprint Neurotherapeutics Network (BPN) encourages applications from small businesses seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis including under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize promising hit compounds through medicinal chemistry, or at the Development stage, to advance a development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Projects that enter at the Discovery stage and meet their milestones may continue on through Development. BPN awardee institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN contractors (and thereby control the patent prosecution and licensing negotiations) for drug candidates developed in this program.

The purpose of the NIH Mentored Research Scientist Development Award (K01) is to provide support and "protected time" (three to five years) for an intensive, supervised career development experience in the biomedical, behavioral, or clinical sciences leading to research independence. Although all of the participating NIH Institutes and Centers (ICs) use this support mechanism to support career development experiences that lead to research independence, some ICs use the K01 award for individuals who propose to train in a new field or for individuals who have had a hiatus in their research career because of illness or pressing family circumstances. Other ICs offer separate K01 FOAs intended to increase research workforce diversity.